B. Riley Securities Downgrades Viridian Therapeutics to Neutral, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Kalpit Patel downgraded Viridian Therapeutics (NASDAQ:VRDN) from Buy to Neutral and reduced the price target from $25 to $20.

May 09, 2024 | 10:04 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Viridian Therapeutics was downgraded by B. Riley Securities from Buy to Neutral with a price target reduction from $25 to $20.
Analyst downgrades typically lead to a negative short-term impact on the stock price as they reflect a less optimistic view on the company's future performance. The reduction in the price target further emphasizes the analyst's lowered expectations for the stock, likely leading to decreased investor confidence and a potential decrease in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100